Regeneron finds enough signal to continue testing COVID-19 antibody cocktail in subset of hospitalized patients

Data announced by Regeneron Tuesday carves out a potential window for COVID-19 mAb therapies in hospitalized patients, an indication where mAbs from the company and its competitors have yet to prove out.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said a futility analysis of its casirivimab/imdevimab antibody cocktail in hospitalized patients on low-flow oxygen support suggested there was enough benefit to continue testing the regimen in this population.  ...